Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING) following the company's fourth-quarter 2025 update. The firm emphasizes that the regulatory focus for Cingulate's lead candidate, CTx-1301 for attention-deficit/hyperactivity disorder (ADHD), has shifted to manufacturing (CMC) rather than clinical performance. The New Drug Application (NDA) remains under FDA review under the 505(b)(2) pathway, and recent financing, intellectual property progress, and commercial buildout efforts support the broader investment thesis.
According to the update, Cingulate completed a $12 million private investment in public equity (PIPE) in February 2026, resulting in a pro forma cash balance of approximately $23 million. Stonegate estimates this provides runway into late 2026. Combined with ongoing access to capital through its at-the-market (ATM) and equity line of credit (ELOC) facilities, the company is positioned to fund ongoing regulatory and manufacturing activities as it resolves remaining CMC items.
Key takeaways from the update include that FDA feedback has been limited to manufacturing and CMC issues, with no safety or efficacy concerns. This positions the remaining work as addressable process validation rather than clinical risk. While regulatory timing may shift, approval remains likely, as the delay is driven by manufacturing validation, not fundamental issues with the product profile.
Cingulate targets the large ADHD market, where a 1% market share implies approximately $250 million in revenue potential for CTx-1301, primarily targeting the booster-dose segment, as disclosed by the company.
For more details, the full announcement is available here.
